This amount reflects total healthcare system costs for initial breast, cervical, colorectal, lung and prostate cancer screening. The largest share of the total cost was CRC screenings via colonoscopy, accounting for $23.7 billion, or 55% of the total. All other CRC screenings combined accounted for another $3.8 billion.
Significantly, the study also found that the $43.2 billion total was less than the reported cost of cancer treatment within the first 12 months after diagnosis, an indication of the cost-effectiveness of early screening, according to the study.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
